This page shows the latest Algeta news and features for those working in and with pharma, biotech and healthcare.
He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.
9bn it paid for the drug's developer Algeta last December.
Acquires Dihon Pharmaceutical as Algeta takeover closes. . Bayer has boosted its consumer healthcare operations in emerging markets with a deal to acquire China-based Dihon Pharmaceutical Group. ... year. By the extended deadline of February 26 the
The bid represents a premium of 37 per cent over Algeta's closing price on November 25 when the initial offer was made. ... Algeta chief executive Andrew Kay said last month the drug had shown "excellent momentum" thanks to rapid endorsement by the US
Algeta made the announcement after reports in the media suggested Bayer was offering NOK 306 per share for the company. ... One unanswered question is whether Algeta has some other hidden gems in its pipeline.
Bayer acquired Xofigo from Norwegian company Algeta in 2009. The deal granted full commercialisation rights in Europe to Bayer while in the US Bayer co-promotes the drug with Algeta.
More from news
Approximately 4 fully matching, plus 6 partially matching documents found.
Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta). The companies will jointly fund the phase III
Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.
Algeta, has been noted as being rather ungenerous, with room for upping the offer. This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under ... with Algeta under which there was US co-promotion for 50 per cent of
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey &Company's pharma and healthcare practice.
He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods
Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta. ... Aksnes was most recently VP clinical research at Algeta, which was taken over by pharma giant Bayer
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...